Stockholders' Equity |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stockholders' Equity |
5. Stockholders’ Equity
As of March 31, 2021, 452,781 shares of the 908,242 shares of the common stock grant had vested at approximately $1,018,757 value and 455,461 shares remain unvested and unrecognized at approximately $1,024,787 value. An aggregate of 73,356 shares of common stock were vested at approximately $165,051 value in January, February, and March 2021 in consideration for services rendered.
On January 29, 2021, in connection with our December 2020 follow-on offering, the underwriter exercised its option to purchase 70,000 additional shares of common stock at the public offering price of $40.00 per share for gross proceeds of $2,800,000 and net proceeds of $2,548,000, after deducting underwriting discounts and commissions and offering expenses borne by the Company, which totaled $252,000.
Warrants
At March 31, 2021, outstanding warrants to purchase shares of common stock accounted for as equity or liabilities were as follows with an aggregate intrinsic value as of March 31, 2021 of $3,438,658 based on the March 31, 2021 closing share price of $34.09:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||